Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intelligent risk communication: can it be improved?

Andrzej Czarnecki1

  • 1Global Patient Safety, Lilly Research Centre, Erlwood Manor, UK. czarnecki_andrzej@lilly.com

Drug Safety
|December 22, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thomas precession, relativistic torque, and non-planar orbits.

The European physical journal. C, Particles and fields·2025
Same author

Corrigendum to "Lactic acid fermentation of osmo-dehydrated onion [Food Chem. 399 (2023) 133954]".

Food chemistry·2022
Same author

Lactic acid fermentation of osmo-dehydrated onion.

Food chemistry·2022
Same author

Protocatechuic acid and quercetin glucosides in onions attenuate changes induced by high fat diet in rats.

Food & function·2020
Same author

The effect of osmotic dehydration on the polyphenols content in onion.

Acta scientiarum polonorum. Technologia alimentaria·2020
Same author

Neutron Lifetime and Axial Coupling Connection.

Physical review letters·2018
Same journal

Implementation Aspects of a Medicines Shortage Policy Tool: Evidence from Australia's Serious Scarcity Substitution Instruments.

Drug safety·2026
Same journal

Availability and Communication of Risk Management Strategies for Pregnancy Category X Medicines across Australian Medicine Information Sources.

Drug safety·2026
Same journal

The Bidirectionality of Lawyer Reporting Bias in Disproportionality Analysis.

Drug safety·2026
Same journal

Safety of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Longitudinal Analysis.

Drug safety·2026
Same journal

Developing a Hierarchical Algorithm to Identify Pregnancies and Determine Gestational Age from Nationwide Linked Health Data in Taiwan.

Drug safety·2026
Same journal

Safety and Effectiveness of Direct Oral Anticoagulants Versus Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis: A Systematic Review and Meta-analysis.

Drug safety·2026
See all related articles

Effective drug risk-benefit communication requires collaboration among patients, physicians, and regulators. Improving this communication is essential for patient safety and better healthcare outcomes.

Area of Science:

  • Pharmacovigilance
  • Medical Communication
  • Health Policy

Background:

  • Significant resources are dedicated to drug development, safety assessment, and risk-benefit communication.
  • Current communication practices often fail to adequately convey the complexities of drug risks and benefits.
  • Misunderstandings in risk communication persist even among healthcare professionals, hindering optimal patient care.

Purpose of the Study:

  • To highlight the importance of effective risk-benefit communication in drug therapy.
  • To identify challenges in current risk communication strategies.
  • To advocate for a collaborative, multi-level approach to enhance drug risk communication.

Main Methods:

  • Review of current practices in drug safety assessment and communication.

Related Experiment Videos

  • Analysis of challenges in understanding and conveying risk-benefit information.
  • Discussion of the need for improved communication strategies involving diverse stakeholders.

    • Main Results:

    • Existing risk-benefit communication efforts are often insufficient.
    • The concept of drug-associated risk is challenging for many to accept.
    • Improved communication requires extensive development and multi-stakeholder cooperation.

    Conclusions:

    • Intelligent risk-benefit communication needs development across multiple levels.
    • Collaboration between patients, physicians, regulators, scientists, journalists, lawyers, and government is crucial.
    • Addressing these aspects in everyday practice will benefit all stakeholders in the future.